Corbus Shares Rise After CRB-913 Obesity Trial Data

Corbus Pharmaceuticals shares rose following positive Phase 1b clinical trial results for its oral obesity drug candidate, CRB-913, demonstrating a 5% mean weight loss at 12 weeks. The CANYON-1 study results arrive as pharmaceutical developers compete to capture market share in oral weight-loss treatments, a sector where earlier competitors faced safety hurdles.

"From a clinical practice perspective, a substantial number of patients with obesity either cannot tolerate GLP-1 receptor agonists or do not achieve an adequate therapeutic response," said Harold Bays, M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center/Monroe Biomedical Research, Clinical Associate Professor at the University of Louisville School of Medicine, and an investigator on the CANYON-1 trial, according to a GlobeNewswire release.

Trial Details and Weight Loss Metrics

According to the CANYON-1 study announcement, the daily oral administration of CRB-913 at a 60 mg dose yielded a statistically significant and clinically meaningful mean weight loss of 5% after 12 weeks of treatment. Trial data indicated that no plateau in weight reduction was observed during the study window, suggesting potential continued efficacy over longer durations.

The findings address a persistent challenge in metabolic disease management. While injectable GLP-1 receptor agonists dominate current obesity care, gastrointestinal side effects frequently cause discontinuation or dosing adjustments among patients.

Market Response and Trading Data

In public market trading as of 2026-09-16T13:50:10.000Z, Corbus Pharmaceuticals Holdings Inc (CRBP) shares traded at $7.44, marking a 7.51% increase from the previous close of $6.92, according to Finnhub market data.

The valuation movement reflects investor sensitivity to early-stage clinical catalysts in the obesity therapeutics sector. Development programs targeting alternative pathways often face heightened scrutiny regarding neuropsychiatric side effects, a historical stumbling block for prior CB1 receptor inverse agonists.

Safety Context and Competitor Challenges

Earlier in the development cycle, management highlighted safety differentiation as a central objective for the program. At a Jefferies investor event in June, Corbus CEO Yuval Cohen, Ph.D., addressed the competitive environment by noting that "pretty much the only question is are we going to look safer than monlunabant in terms of the neuropsych [adverse events]," as reported by FierceBiotech.

Previous attempts by major drugmakers, including Sanofi and Novo Nordisk, to target the cannabinoid receptor system for metabolic indications were curtailed due to psychiatric adverse events such as depression and anxiety. The CANYON-1 trial data release represents an incremental step in establishing whether selective peripheral targeting can circumvent those historical toxicities.